Markets

Ligand, SAGE Captisol Partnership to Also Include SAGE-689

A stock chart on display
Credit: Shutterstock photo

Ligand Pharmaceuticals IncorporatedLGND expanded its existing partnership with SAGE Therapeutics, Inc. SAGE and announced that their global license and supply agreements will now include the use of Captisol for the development and commercialization of SAGE-689.

Ligand received a licensing fee and the deal could see the company receiving milestone payments, tiered royalties on future net sales plus revenues from Captisol material sales. SAGE will fund all costs related to the program

We note that SAGE is developing SAGE-689 as an adjunctive intravenous treatment of patients with status epilepticus whose seizures have not been resolved after treatment with standard-of-care therapies.

We remind investors that Ligand had struck a Captisol license agreement with SAGE in 2011. The deal covers the development and commercialization of Captisol-enabled therapeutics for a broad range of debilitating central nervous system conditions including SAGE's lead pipeline candidate, SAGE-547. Currently, SAGE-547 is in phase III development for the treatment of patients with super refractory status epilepticus.

We are positive on the latest agreement between Ligand and SAGE. Ligand's Captisol formulation technology has resulted in partnerships with several leading health care companies like Novartis AG NVS and Amgen Inc. AMGN among others. These partnerships not only provide the company with funds in the form of milestone and royalty payments but also help drive top-line growth.

Ligand is a Zacks Rank #4 (Sell). Amgen is a better-ranked stock in the health care sector carrying a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AMGEN INC (AMGN): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

LIGAND PHARMA-B (LGND): Free Stock Analysis Report

SAGE THERAPEUTC (SAGE): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AMGN LGND SAGE NVS

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More